Bispecific Antibody & Cancer

Patent Landscape Analysis

January 2025



SAMADIA

TABLE OF CONTENTS

INTRODUCTION	5
- BsAb for cancer therapy	
- Scope of the report	
- Reading guide	
- Main patent assignees	
EXECUTIVE SUMMARY	11
PATENT LANDSCAPE OVERVIEW	16
- Time evolution of patent publications	
 Ranking of most prolific patent applicants 	
- Current legal status of the main players	
- Patent legal status of the corpus	
- Mapping of main current IP holders	
- Time evolution of main patent assignees	
NEWCOMERS	24
- Startup companies	
- Established companies	
COLLABORATIONS	32
IP POSITION OF MAIN APPLICANTS	46
- IP leadership of patent applicants	
- IP prior art blocking potential of patent applicants	
- Key patents	
 Strength index of patent portfolios 	
MAIN EP PATENT OPPOSITIONS	54

PATENT SEGMENTATION

- Definition
- Main assignees by technology
- CD3
- Immune Checkpoint
- Tumor Antigen

IP PROFILE OF KEY PLAYERS

- Overview, key patents & clinical trials of:
- Amgen
- Genentech
- Roche
- GenMab
- Janssen
- Regeneron
- Xencor

METHODOLOGY

- Patent search, selection and analysis
- Search strategy
- Terminologies for patent analysis
- Strength and blocking potential

KNOWMADE PRESENTATION	122
CONTACT	126

SAMIDIA

2

60

71



THE AUTHORS



PhD Fabienne Massa

Fabienne works for Knowmade in the field of Biotechnology and Life Sciences. She holds a PhD in Molecular and Cellular Biology from the IPMC (Sophia Antipolis, France). She also holds a Master of Business Management from IAE (Nice, France) and she previously worked in the pharmaceutical industry. Contact: fabienne.massa@knowmade.fr



PhD Brice Sagot

CTO and co-founder of KnowMade. He leads the Biotechnology and Life Sciences department. He holds a PhD in Molecular Biology from the University of Nice Sophia-Antipolis (France).

Contact: brice.sagot@knowmade.fr



SANAD

3

Specialized in analysis of patents and scientific information. Knowmade provides Technology Intelligence and IP strategy consulting services. The company is supporting R&D organizations, industrial companies and investors in their business development by offering them a deep understanding of the technology trends and their IP environment. Knowmade operates in the following industrial sectors: Microelectronics, Compound Semiconductors, Power Electronics, RF & Microwave Devices, MEMS Sensors & Actuators, LED/OLED, Imaging & Display, Photonics, Battery, Manufacturing & Advanced Packaging, Micro & Nanotechnology, Biotechnology, Cellular & Molecular Biology, Microbiology, Dermatology, Pharmacology, Oncology, Immunology, Medical Devices & Medical Imaging, Agri-Food & Environment. Knowmade performs prior art search, patent landscape analysis, scientific literature analysis, patent valuation and freedom-to-operate analysis. In parallel, the company proposes litigation/licensing support, technology scouting and IP watch service. Knowmade's analysts combine their technical and patent expertise by using powerful analytics tools and proprietary methodologies to deliver relevant patent analyses and scientific reviews.

We Know Technology, We Know Patents



- This report provides a detailed picture of the patent landscape for **Bispecific Antibody & Cancer**.
- This report covers patents published worldwide up to August 2024.
- We have selected and analyzed about +2890 patent families relevant to the scope of this report.



h

Included in the report

- ✓ All cancer: hematological cancers (e.g., leukemia, lymphoma), solid cancers (e.g., prostate cancer, melanoma) and virus-induced cancers (e.g., HPV, EBV)
- All antibody formats: bispecific, trispecific, tandem, diabody, crossMab, etc.
- ✓ All antigens / epitopes recognition: tumor antigens (e.g., PSMA, BRCA), immune checkpoints (e.g., PD-1, CTLA-4) and immune cell receptors (e.g., CD3, CD28)

Not included in the report

- X Other therapeutic applications: virus or bacteria infection, diabetes, cardiovascular pathology, etc.
- X Drug coupled to an antibody: antibody drug conjugate
- X Radio-molecule coupled to an antibody: radiopharmaceutical
- X Bispecific chimeric antigen receptor



INTRODUCTION Key features of the report

- **Excel database** comprising all analyzed patents of the report is provided.
- This **patent database** allows multi-criteria searches, including:
 - Patent publication number
 - Hyperlinks to the original documents
 - Priority date
 - Title

(C) Know Made


- Abstract
- Patent assignees
- Technical segmentation
- Legal status for each member of the patent family.
- The findings, interpretations and conclusions expressed in this report are entirely those of Knowmade and may not constitute or imply endorsement by a decision-making body such as a court of law or a patent office. Any assessment of the effect or scope of pending applications or granted patents reflects our own views and these are not necessarily those of a Patent Attorney. Should confirmation of our assessment in this respect be required, we recommend that you seek the advice of a national Patent Attorney.






Patent Landscape Overview

Patent assignees, IP dynamics, patent legal status, patent geographical coverage







Patent Landscape Overview

Identify main EP oppositions, collaborations and newcomers

MAIN EP PATENT OPPOSITIONS

Main oppositions on EP patents (1/5)

This table shows main oppositions filed against European patents. For each opposed patent, application date, assignee, opponent, opposition year and results are presented.

Assignee	Opposed Patent	Application filing date		Opponent	Opposition year	Title		Result					
A STAR	073420130	1016-86-85		Tenenibin	2821. 82/beta/cz	remon gamma chain a	riboles	Ongoing					
ABSHIE	073024287	2005-02-17	Weiss N	IP COLLABOR	ATIONS								
ABL/PRC	673045435	2014-89-20		Main IP collabo		2)							
ATHS	673131926	2014-04-33				-/							
	03463483	2017-02-02		Co-assig	gnees	Organization type	Representa members	of Link	st publication years Title				
	EP2070484	2014-03-03	Walls	A344777	INS MANOPENEN		patent fami						
	ERCTRUCK.	2012-01-04	Jumssen Pool	INVESTIGATION OF ANY ANY	INVESTIGATION	holustrials	EPHLER.	IP NEWC					
			Pate	ANUBO	I MAR BUTTUARA.	Industrials	1710485	Startup co	mpanies (2/3)				
AMOEN	EP2780575	2012-13-34	ABC Regard	A84.800	I MAR NUPRARMA	Industrials	Dises a	Assignee	Company information	Company size	Patent family	Main relevant selected patent family	
	CP2002054	2013-00-27		A84.800	I MAS NOPULASA.	Industrials	1256624		None Rospinson (a wholly-owned subsidiary of 1986) Heldings) is a global bistechnology US			000 despeting antibady-and-set thereof (2003002/001222 = 2004) The paramit famile describes 003-targeting enfloadies and hispecific artificoles targeting both 000 and	
	173038148	2013-00-27		ABLIEG	I MAR BUPTARMA	tolustrials	NO232553		company, founded in 2003, which provides a solution from "lates to IND", ranging from target validation			pascarst antigers. Arti-CBI Ali comprise a H4H fragment (single-valiable demain VN of heavy-chain Ab). Anti-BNM antibady. and dependin antibady and use (Anno) [1042271322 - 2023).	
	673452687	2011-00-27		APRIMED	artisten socialis	Industrials	NO25212		and Ab discovery through preclinical seasarch. The integrated Ab and Ab discovery services with	The		The invention relates a RTHL-targeting antibudy that binds human RTHL and synamology macagae RT does not cross-react with other RT family members. It exhibits good anti-tumor activity, T-cell activation in	
* Companies acting as a fr	ont for other parties to o	conceal their identitie	es (straw mai	AFTONED	ARTINA BOTHEMAPOUTICS	Industrials	N020238	NONA	multiple modalities range from antigen preparation, animal immunication, single 8 cell screening, to 45	> 50		and in-vitro experiments. It is also described a bispecific antibody targeting #144 and CBL, which has a half-life, relates good stability and hydrophilisity, and reduces fasticity while resuring #flasty.	
(nowMade				APRIMED	ARTINA BOTHOMPOUTION	Industrials	NO25234	BIOSCIENCES	load generation and engineering, developability essessment and pharmacological evaluation, leveraging advantages of Harbour Mior* platforms	÷.		4.188 Uniting protein and application through <u>EPE103115</u> - 30000 The 4-308-binding protein of this investigation is a fully human antibody having the binding activity to human and presentation manage 4-308. Some 4-308-binding portains are only fully the size of porvertion.	
				-	MEMORIAL BLAM SETTEMPS		(PSM)		and the experienced therapeutic Ab disessory team.			and symmetry is many many many and a series where the series and any new series of common antibudies, they can be well used for impecific antibudies.	
				HOERING	CANCER CONTER, LUEWIS INCLUSIVE FOR CANCER INCLUSION	industrial Asselensis	TPIMA					Activated in SuperSic and CDR and and PD-L2 proteins and uses thereof <u>Tencology (UTL2)</u> – 2003) Provided are protein that specifically lend PD-L2 and exhibit activatable specific CDI binding in cancer taxae	
				AREO PROMINENTINAS	AD PROMINENTS TO ALL	Industrials	194444	CENTESSA PLAN	Contense. Pharmacountrals is a US chirostistage SA attannaoundral company, hounded in 2015, with a 8560 that aims to discover and develop metiones with indications in tare discusses and immuno- encodegy.	A pharmacoutical company, founded in 2021, with a			Activetable Migner(Br. and CD47 and and PD42 provides and user (Anne) (<u>AC1023/144421</u> - 2033) Provided are pressin that genefically blind PD42 and exhibit estimatable specific (D47 binding in concernities
				AREO PRANKETS TOALS	DRINGHEN ONPECASEN BOSCIENCIS	Industrials	WCCODIA					Activotoble Mapacific antihodies comprising a linker, <u>production control</u> = 0000 8 proteins comprising a 2 st materie capatitie all'banding to a individue expensate in a diseased traces, a peptide relevande by a pretexer expensate in a diseased traces, and a 2 st motivity capable of locating in a ex-	
				(C)KnowMade					Indvetermente Therapeutics is an American			expressed in the diseased tissue. The binding of the 3-timelety is inhibited when the populae inker is unclus Condensates of biopecific antiocdes and chinesic antigen recogner F with for recomment (WE1004/1104/1-	
									community descendent in 2020. We economications			The investigal provides both comprising a 2° antigen landing region that binds to a modified T cell, a 2° a binding region that binds to the turner cell, and a 3° antigen binding region that binds to any other artigen.	
								Unerare offics	immune activation and tamor cell targating in a single agent. Through integrated T cell signaling, its	= 11		Repectitic antibody facilier maticules and motheds of sore thereof InfOCLIALINES2 - 3004. The patient family describes table that faired to 2018 and 2019. The Athene optionally funds with a CD58 people	
									biologics directly targets terrier cells and provides patent, locar-localized termine amplification at the turnor situ to maximize turnor killing.			Repectific antibody future materialis and methods of nor interest <u>pressession 2000</u> - 2000). The patent family presides compositions and methods for the efficient production of a between-al antibodies, such as a bisocoffic architecture.	

(C) KnowMade



(C) Know Made


7

© 2025 All rights reserved | www.knowmade.com

SAMIDIC

Patent Portfolios Benchmarking: Beyond the Quantity

Who has the best patent portfolio?




IP POSITION OF PATENT APPLICANTS

53

Prior Art Blocking Potential

Blocking potential increases when the number of forward citations (i.e., search report or description mbines with a high number of



nber of forward citations (excluding self-citations)

folio level. The identification of a "blocking patent" requires an in-depth specific nt from the patent families. The IP blocking potential is an indicator of how an IF t to circumvent in a technoloay. The IP blocking potential is not necessarily linked

Potenti partifalian artifa a Nigh prior art iP blocking potential are edword is evoluting the potentability of potent applications Med allowards, citil potent families are more likely to resolve a high number of citations from subsequent applications. Therefore, well-clied patent families are likely to be relevant prior art "blocking" for patenting articly of competitors i.e., presenter and many hands or access where

SAMPOIN

Reader's patient per think has been bliretified as over of the work. hanky good to the first of impecific antibody and cancer postness, searing clubbes from vertices accounts such as the University of Sease, the University of Stanford, the University of Collectia or the Instale Maximilians University or various industrialitie such as Herserity, March 1982, 13 Mile, Addring, Introdements, Samagea, Sencer or Plant.

Milway's BHE has only 23 point families. Its paint perifulie seasod a halt number of citations, wordy for its 3 potent beniles, published between 1994 and 1998 SPECIESAS, INSURANCE, DISCHARGE These patent families are cled by around key players in hispatific arbitrary area such as bachs, Department, Greenals, Brease, Reprintant, Machappeles, Speed and other. BMS Net regularly potent families in this field even if It is not the company's main activity,

Regards patent particle is play very stast. The company holds the most highly-chod patent families in the area of hispatific estimate with several 350 forward chatters for 3 patient keniles find by Microsoft Languised in 2017) between 2009 and 2008 REALTING CONTRACT DESIGNATION.

> Bispecific antibody and cancer - Patent Landscape Analysis - Ref. : KMxxxxx 49 © 2025 All rights reserved | www.knowmade.com




Patent Segmentation What are the key IP players for each segments?

Patent families were segmented into the following categories:

- Tumor antigens: ERBB family. BCMA, BRCA, mesothelin, PSMA, CEA, claudin, EPCAM, mucin, NKG2D, VEGF, CEACAM, MAGE, ROR1, c-Met and nectin.
- Immune checkpoints: PD1 / PDL1, CTLA-4, LAG-3, TIM-3, OX40, ICOS, B7-H3, TIGIT and BTLA,

• T cell receptor: CD3. Although alternative T cell targets, such as the αβTCR and T cell surface glycoprotein CD5, have been explored to redirect or engage T cells. bsTCEs targeting CD3s are the most advanced



This table shows which segment the parameterized by the main IP players belong to. Memory all players develop various Mappedile antibodies. Regarding Roche and Regard, the major players, they are bicased on T will orgage (CDI binding). One difference between them is that despections not have patent keetly describing fulls against investor checkpoint 10. On the contrast, Beneric potent periods has a lot of potent families as report C 1000. Must of the table described in scientific and patient publications describe a bridge between 10th on T self and 'N on-cancer cell. However, Dragently, Therapeutics, in 20 company founded in 2006, fee optical fair a different strategy by focusing on NK cells with InAb bridging NVG2D on FM at 30 an cancer calls, it is also interesting to note the specificity of banaving, which in the only it player for and on only one segment transmissional



Overview: definition

Checknoints (IC

53

37

15

Draw of the attractive features of ballos is their patential to sliquide activity that is not present in any contribution of parent architecture, industry, holds generate a new functionality depending on the physical integer of the two uncertainties and second to combining seconds antibulies with the same uncertainties. Inspace of this associated morel activity, and anticodes have been defined adjustmention balls, balls that bridge only a their adjuster enclosing of artise represent the logaritument, around an any other adjustmention of artise represent the logaritument around an artise result of a statement of a state demonstrative. The strength of collection bodies is their shifts to callede sough hereforegings that remains have beeing inactification to be conserved in the same molecule. We can be exploited for instruction therapeutic sprought, for instance, to bridge two cell types (instrum binding) or to engage two indicates as the mentionee of one cell (in-do binding). These concepts require simultaneous binding of the transport Baltice, while other shighte screepts are based on sequential binding of the transitioning domains (Spares Indine).

a Bridator reasonance high intervals antibude induces inco how a detainers (1900) as a speer cancer of an income Conduction (100) as a speer (2000)


an sancer cell and CDE on Troil

63

had into contract presenter based or these princip

IGA, masothelin, ISAA, ISA, risudin, SIKIAA, musin, HIRKED, VERF, ISAGAM, MAGE, IORS, I-MAT and nextur-A. LAG.3, TAN.5, GRAD, KONS, KO.HS, THEFT and HTLE.

or Turil tensity, such as the self-Di and Taril suchase plasareties (DI, have been malaretic an engage Turily,





SAMO

9




(C)KnowMade

100

(C)KnowMad

IP profile of key players IP portfolio summary, IP strategy, key patents and clinical trials

A focus on the 7 main players is provided in a dedicated section. For each player, the Bispecific Antibody for cancer treatment patent portfolio is statistical analyzed to provide an overview of its strengths and level of IP activity. The key patents of the player have been identified thanks to clinical trials.





Excel file with all patents analyzed in the report

A	В	C	D	E General information	F	G	н	I	J	K Segmentation	
Family number 🔽	Patent number	Patent assignee	Title	Abstract	Earliest publicatior date	Forward citation	PDF link	Biblio summary 🔽	CD3	Checkpoint inhibitors	Tumor ai
11694129	05202404255616 PK144225 PK144225 US20230340160 JP7175291 BR112014003769 CA2837375 IL268886 EP3892640 ES2857734 PL3221286 EP3321286 MM335520	ROCHE	(EP3892640) Bispecific t cell activating antigen binding molecules	(EP3892640) The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynuclectides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynuclectides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.	2013-02-28	US201200216522(0511 370632 WO201506749 US20100322334;US8 703132 WO201636918 US20140243505;US9 079365 US20160075785;US9 914776 US20160075785;US9 914776 US20160075785;US9	<u>Open</u>	Open	×		
11224666	MX336520 EP4023670 AU202067284 CN108546300 IN390990 VN0030615 CN113667020 CN107038975 EP3485901 CN106977606 KR10-2021-0013324 KR10-2210136	JANSSEN	(EP4023670) Egfrand c-met-fibronectin type iii domain binding molecules Pate	(EP4023670) Monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules, isolated nucleotides encoding the molecules vectors host cells and methods of making thereof are useful in the generation of the apeuto molecules and treatment and diagnosis of diseases and disorders. Intinformation	2014-05-30	42578 US20210077638;US11 896682 W0201670816 EP3885344 JP2018520675 W0202402235 EP3216786 US20170355696;US10 179784 US20160214978:US10	Open	Seg	gme	ntat	, ioi
11136189	WO2024/173607 WO2024/173607	EVOLVEIMMUNE THERAPEUTICS	(WD2024173607) Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment	(WD2024/173607) The present disclosure provides bispecific antibodies comprising a first antigen binding region that binds to a modified T cell or CAR domain expressed on a modified T cell, a second antigen binding region that binds to the tumor cell, and an at least third antigen binding region that binds to a biological molecule, e.g., a cell surface antigen, e.g., a disease associated antigen). Also included are methods of use thereof, including T-cell re-targeting, and treating cancer in a subject in need thereof.	2024-08-22		<u>Open</u>	Open	×		×
11136042	WO2024/173376 WO2024/173376	LAVA THERAPEUTICS	(WD2024173376) Combination therapy comprising multispecific gamma delta tor antibodies	(WD2024/173376) The present disclosure relates to a method for the treatment of cancer comprising administration to a subject in need thereof, of a multispecific antibody comprising a first antigen-binding region capable of binding a human cancer antigen and a second antigen-binding region capable of binding a human Vy9V82 T cell receptor, in combination with a common gamma chain cytokine and/or an immune checkpoint inhibitor.	2024-08-22		Open	Open			×



Online database with all patents analyzed in the report

Useful online patent database with updated legal status

 \sim

~

Bispecific t cell activating antigen binding molecules

Abstract

The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.

Images (99)			
	1 - 27 12 - 27 12 - 27	1940 - 1945 1940 - 1945 1940 - 1945	
•	1911 111	5426 - 44 - 5	9 - 1020 2-22

Classifications

Claims

(EP3892640)

1. A T cell activating bispecific antigen binding molecule comprising

(i) a first antigen binding moiety, which is a Fab molecule capable of specific binding to an activating T cell antigen,

(ii) a second and a third antigen binding moiety, which are each a Fab molecule capable of specific binding to a target cell antigen, and

(iii) an Fc domain composed of a first and a second subunit capable of stable association; wherein (a) the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the first antigen binding moiety, and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain of the first antigen binding moiety, and the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain to the N-terminus of the Fab heavy chain of the second antigen binding moiety is fused at the C-terminus of the Fab heavy chain to the N-terminus of the first or the second subunit of the Fc domain; and wherein the T cell activating bispecific antigen binding molecule comprises not more than one antigen binding moiety capable of specific binding to an activating T cell antigen.

2. The T cell activating bispecific antigen binding molecule of claim 1, wherein the activating T cell antigen is CD3.

3. The T cell activating bispecific antigen binding molecule of claim 1 or 2, wherein the first and the

EP3892640 A1

GRANTED ALIVE

🔎 Download PDF

Assignee ROCHE GLYCART

Inventor AST OLIVER • BRUENKER PETER • FAUTI TANJA • FREIMOSER-GRUNDSCHOBER ANNE • JAEGER CHRISTIANE • KLEIN CHRISTIAN • MOESSNER EKKEHARD • UMAÑA PABLO

 Protected
 ■ DE + ■ NO + ■ RS + ■ BE + ● FI + ■ TW + ■ PT + ■ BG + ● JP + ■ DK

 countries
 ■ LT + □ HR + ■ FR + ■ UA + □ HU + □ BR + ■ SE + ■ MA + □ SG + ■ SI

 + □ SK + ■ GB + ■ IE + □ GC + ■ CA + □ IL + ■ CH + ∞ KR + ■ ZA + ■ CN


 + □ EP + □ GR + ■ IT + ■ MX + ■ MY + □ ES + ■ AT + ■ AU + ■ CZ + □ VN

 + □ PF + □ RO + □ NL + □ TR + □ IN + ■ PE + □ CL + ■ CO + □ US

 + □ CR

Patent family overvi	ew	Applications • Pub	lications • Legal statu	s 🔨
Applications	Publication number	Application date	Legal status	
C PK	PK144225	2012	Granted	R
WO	W02013/026833	2012	Lapsed	R
CA	CA2837975	2012	Granted	R
AU	AU2012298537	2012	Granted	R
	IL229765	2012	Granted	R
KR	KR10-1963923	2012	Granted	R
CN	CN103748114	2012	Granted	R
MX	MX352101	2012	Granted	ß
O EP	EP2748201	2012	Granted	R
- C PT	PT2748201	2012	Granted	R
DK	DK2748201	2012	Granted	R
- 💶 LT	LT2748201	2012	Granted	R
ES ES	ES2659764	2012	Granted	£







ORDER FORM

Bispecific Antibody and Cancer

Patent Landscape Analysis – January 2025

Ref.:KM25001

Check

ORDER

SHIP TO

Job Title:

Company:

Address:

City:

State:

Postcode/Zip:

VAT ID Number for EU members:

Country:

Tel:

Email:

Date:

Name (Mr/Ms/Dr/Pr):

To pay your invoice using a bank money wire transfer please contact your bank to complete this process. Here is the information that you will need

Bank: Banque Populaire Méditerranée, CAP 3000 Quartier du lac. 06700 St Laurent du Var. France

In order to pay your invoice via PAYPAL, you must first register at www.paypal.com. Then you can send money to the KnowMade S.A.R.L. by entering our E-mail address contact@knowmade.fr as the recipient and entering the invoice amount.

reception.

*The report can be shared with the employees of the Company purchasing the report. Subsidiaries and joint-ventures are excluded. Please be aware that the report is watermarked on each page, with the name of the recipient and the organization (the name mentioned on the PO). This watermark also reaffirms that report sharing is not allowed.

I hereby accept Knowmade's Terms and Conditions of Sale

PAYMENT METHODS To pay your invoice using a check, please mail your check to the following address: KnowMade S.A.R.L. 2405 route des Dolines 06902 Valbonne Sophia Antipolis FRANCE **Money Transfer** to submit the payment: Pavee: KnowMade S.A.R.L. IBAN: FR76 1460 7003 6360 6214 5695 139 **BIC/SWIFT: CCBPFRPPMAR** Paypal **RETURN ORDER BY** E-mail: contact@knowmade.fr Mail: KnowMade S.A.R.L., 2405 route des Dolines, 06902 Valbonne Sophia Antipolis, FRANCE **PRODUCT ORDER** €4.990 – Multi user license* Signature: For price in dollars, please use the day's exchange rate. For French customer, add 20% for VAT. All reports are delivered electronically in PDF format at payment

SAMIDIA

Terms and Conditions of Sales



DEFINITIONS

"Accentance": Action by which the Buver accepts the terms and conditions of sale in their entirety. It is produce sufficient evidence of such defects. done by signing the purchase order which mentions "I hereby accept Knowmade's Terms and Conditions of 2.6 No return of Products shall be accepted without prior information to the Seller, even in case of delayed containing contaminating or destructive properties before making the Products available, the Seller cannot Sale"

"Buver": Any business user (i.e. any person acting in the course of its business activities, for its business under article 2.5 shall remain at the Buver's risk needs) entering into the following general conditions to the exclusion of consumers acting in their personal intoracte

"Contracting Parties" or "Parties": The Seller on the one hand and the Buyer on the other hand

patents, trademarks, registered models, designs, copyrights, inventions, commercial secrets and know-how, time to time to time. The effective price is deemed to be the one applicable at the time of the order. technical information. company or trading names and any other intellectual property rights or similar in any 3.2 Payments due by the Buyer shall be sent by cheque payable to Knowmade, PayPal or by electronic nart of the world. notwithstanding the fact that they have been registered or not and including any pending transfer to the following account: registration of one of the above mentioned rights.

"License": For the reports and databases, 2 different licenses are proposed. The buyer has to choose one BIC or SWIFT code: CCRPERPPMAR license.

1. Single user license: a single individual at the company can use the report.

2. Multi user license: The report can be shared with the employees of the Company purchasing the report. case, the need of down payments will be mentioned on the order. Subsidiaries and joint-ventures are excluded

include Excel files.

"Seller": Based in Sophia Antipolis (France headquarters). Knowmade is a technology intelligence company specialized in the research and analysis of scientific and technical information. We provide patent are delivered only after reception of the payment. landscapes and scientific state of the art with high added value to businesses and research laboratories. Our 3.4 In the event of termination of the contract, or of misconduct, during the contract, the Seller will have intelligence digests play a key role to define your innovation and development strategy.

1. SCOPE

1.1 The Contracting Parties undertake to observe the following general conditions when agreed by the 4.1 The Buver or any other individual or legal person acting on its behalf, being a business user buying the consequences in their entirety. BE WHOLLY INAPPLICABLE TO ANY SALE MADE HEREUNDER AND SHALL NOT BE BINDING IN ANY WAY ON acts it deduces thereof THE SELLER

1.2 This agreement becomes valid and enforceable between the Contracting Parties after clear and nonequivocal consent by any duly authorized person representing the Buyer. For these purposes, the Buyer 4.3 In no event shall the Seller be liable for: Knowmade's Terms and Conditions of Sale". This results in acceptance by the Buyer.

1.3 Orders are deemed to be accepted only upon written acceptance and confirmation by the Seller, within 17 days] from the date of order, to be sent either by email or to the Buyer's address. In the absence of any on the website, or in the Products: confirmation in writing, orders shall be deemed to have been accepted.

2. MAILING OF THE PRODUCTS

2.1 Products are sent by email to the Buyer:

- within [1] month from the order for Products already released: or

- within a reasonable time for Products ordered prior to their effective release. In this case, the Seller shall progress

2.2 Some weeks prior to the release date the Seller can propose a pre-release discount to the Buyer.

The Seller shall by no means be responsible for any delay in respect of article 2.2 above, and including in 4.6 In the case where. after inspection, it is acknowledged that the Products contain defects, the Seller by the other Party. time to compute or compare the data in order to enable the Seller to deliver a high quality Products.

2.3 The mailing of the Product will occur only upon payment by the Buyer, in accordance with the conditions contained in article 3.

2.4 The mailing is operated through electronic means either by email via the sales department. If the 4.7 The deadlines that the Seller is asked to state for the mailing of the Products are given for information 9. GOVERNING LAW AND JURISDICTION Buyer provided that it is informed of the defective formatting within 90 days from the date of the original download or receipt of the Product.

2.5 The person receiving the Products on behalf of the Buyer shall immediately verify the quality of the first down payment to the exclusion of any further damages. Products and their conformity to the order. Any claim for apparent defects or for non-conformity shall be 4.8 The Seller does not make any warranties, express or implied, including, without limitation, those of and Conditions.

sent in writing to the Seller within 8 days of receipt of the Products. For this purpose, the Buyer agrees to saleability and fitness for a particular purpose, with respect to the Products. Although the seller shall take reasonable steps to screen Products for infection of viruses worms Trojan horses or other codes

delivery. Any Product returned to the Seller without providing prior information to the Seller as required guarantee that any Product will be free from infection

3. PRICE, INVOICING AND PAYMENT

"Intellectual Pronerty Rights" ("IPR") means any rights held by the Seller in its Products, including any annual subscriptions. They are expressed to be inclusive of all taxes. The prices may be reevaluated from

Banque Populaire Méditerranée, CAP 3000 Quartier du lac, 06700 St Laurent du Var, France

IBAN. · FR76 1460 7003 6360 6214 5695 139

3.3 Payment is due by the Buyer to the Seller within 30 days from invoice date, except in the case of a the Product for purposes such as: "Products": Reports are established in PowerPoint and delivered on a PDF format and the database may narricular written agreement. If the Buver fails to pay within this time and fails to contact the Seller, the latter shall be entitled to invoice interest in arrears based on the annual rate Refi of the «BCE» + 7 points, in accordance with article L. 441-6 of the French Commercial Code. Our publications (report, database, tool...) - use in any timesharing, service bureau, bulletin board or similar arrangement or public display;

the right to invoice at the stage in progress, and to take legal action for damages

4. LIABILITIES

Buver and the Seller. ANY ADDITIONAL, DIFFERENT, OR CONFLICTING TERMS AND CONDITIONS IN ANY Products for its business activities, shall be solely responsible for choosing the Products and for the use and 6.4 The Buyer shall define within its company point of contact for the needs of the contract. This person will

4.2 The Seller shall only be liable for (i) direct and (ii) foreseeable pecuniary loss, caused by the Products or arising from a material breach of this agreement

not limited to, damages for loss of profits, business interruption and loss of programs or information) arising out of the use of or inability to use the Seller's website or the Products, or any information provided may be borne by the Seller, following this decision.

thereof

4.4 All the information contained in the Products has been obtained from sources believed to be reliable. The Seller does not warrant the accuracy, completeness adequacy or reliability of such information, which cannot be guaranteed to be free from errors.

the liability of the Seller, provided that the Seller ensures the substituted Product is similar to the Product Buyer. initially ordered

cases where a new event or access to new contradictory information would require for the analyst extra undertakes to replace the defective products as far as the supplies allow and without indemnities or The Seller may, from time to time, update these Terms and Conditions and the Buyer, is deemed to have guaranteed for a maximum of two months starting from the delivery date. Any replacement is excluded for in due time. any event as set out in article 5 below.

Product's electronic delivery format is defective, the Seller undertakes to replace it at no charge to the only and are not guaranteed. If such deadlines are not met, it shall not lead to any damages or cancellation 9.1 Any dispute arising out or linked to these Terms and Conditions or to any contract (orders) entered into information from the Seller. In such case only, the Buyer shall be entitled to ask for a reimbursement of its which shall have exclusive jurisdiction upon such issues.

5 FORCE MAIFURE

The Seller shall not be liable for any delay in performance directly or indirectly caused by or resulting from 3.1 Prices are given in the orders corresponding to each Product sold on a unit basis or corresponding to acts of nature, fire, flood, accident, riot, war, government intervention, embargoes, strikes, labor difficulties, equipment failure, late deliveries by suppliers or other difficulties which are beyond the control and not the fault of the Seller

6. PROTECTION OF THE SELLER'S intellectual property

6.1 All intellectual property rights attached to the Products are and remain the property of the Seller and are protected under French and international copyright law and conventions

6.2 The Buyer agreed not to disclose convirgence during redistribute resell or publish the Product or any To ensure the payments the Seller reserves the right to request down payments from the Buyer. In this part of it to any other party other than employees of its company. The Buyer shall have the right to use the Products solely for its own internal information purposes. In particular, the Buyer shall therefore not use

- Information storage and retrieval systems:

- Recordings and re-transmittals over any network (including any local area network):

- Posting any Product to any other online service (including bulletin boards or the Internet):

- Licensing leasing selling offering for sale or assigning the Product

6.3 The Buyer shall be solely responsible towards the Seller of all infringements of this obligation, whether this infringement comes from its employees or any person to whom the Buyer has sent the Products and shall personally take care of any related proceedings, and the Buyer shall bear related financial

OTHER DOCUMENTS ISSUED BY THE BUYER AT ANY TIME ARE HEREBY OBJECTED TO BY THE SELLER, SHALL interpretations he makes of the documents it purchases, of the results he obtains, and of the advice and be the recipient of each new report in PDF format. This person shall also be responsible for respect of the copyrights and will guaranty that the Products are not disseminated out of the company.

7. TERMINATION

7.1 If the Buyer cancels the order in whole or in part or postpones the date of mailing, the Buyer shall accepts these conditions of sales when signing the purchase order which mentions "I hereby accept a) damages of any kind, including without limitation, incidental or consequential damages (including, but indemnify the Seller for the entire costs that have been incurred as at the date of notification by the Buyer of such delay or cancellation. This may also apply for any other direct or indirect consequential loss that

7.2 In the event of breach by one Party under these conditions or the order, the non-breaching Party may b) any claim attributable to errors, omissions or other inaccuracies in the Product or interpretations send a notification to the other by recorded delivery letter upon which, after a period of thirty (30) days without solving the problem, the non-breaching Party shall be entitled to terminate all the pending orders. without being liable for any compensation.

8. MISCELLANEOUS

4.5 All the Products that the Seller sells may, upon prior notice to the Buyer from time to time be modified. All the provisions of these Terms and Conditions are for the benefit of the Seller itself, but also for its use its best endeavours to inform the Buyer of an indicative release date and the evolution of the work in by or substituted with similar Products meeting the needs of the Buyer. This modification shall not lead to licensors, employees and agents. Each of them is entitled to assert and enforce those provisions against the

Any notices under these Terms and Conditions shall be given in writing. They shall be effective upon receipt

compensation of any kind for labor costs, delays, loss caused or any other reason. The replacement is accepted the latest version of these terms and conditions, provided they have been communicated to him

of the orders, except for non-acceptable delays exceeding [4] months from the stated deadline, without in application of these Terms and Conditions shall be settled by the French Commercial Courts of Grasse,

9.2 French law shall govern the relation between the Buyer and the Seller, in accordance with these Terms



KNOWMADE Company presentation




SANJOIN

KNOWMADE PURPOSE

SAMADIN Turning patent information and scientific literature into actionable insights, providing high value-added reports for **decision-makers** working in R&D, Intellectual Property, Innovation Strategy, and Marketing

Competitive landscape | Technology trends | Opportunities / Risks | R&D and IP strategy





KNOWMADE OFFER

CUSTOM SERVICES

(Tailor-made analysis)

To meet your needs and budget/lead time constraints

> Specific and dedicated report.

Prior-art search, literature review, patent landscape, freedom-to-operate, patent valuation, IP due diligence, technology scouting, monitoring service, etc.

Format

- PDF file with analyses.
- Excel file with data.
- Access to the analyst.

REPORTS (multi-client product)

To understand the competitive landscape and explore the emerging ecosystems and new technologies

- Stand alone report
- > Patent landscape.
- Overview on IP dynamics, trends and players.
- Competitor, technology and strategy analysis.
- > Benchmark of patent portfolios.
- > Key IP players & key patents.

Format

- PDF file with analyses.
- Excel file with patent data.

MONITORS (multi-client product)

To track the latest R&D developments and IP activities, and to be sensitive to weak signals

Annual subscription

- > Patent monitoring service.
- Quarterly updated patent data and technology trends.
- Current R&D and IP activities.
- Early detect weak signals, opportunities and risks.
- > Open discussion with analyst.

Format
PDF file with analyses.
Excel file with patent data.
Direct access to the analyst.

INSIGHTS (free article & webinar)

To get unique information about industry and technology

 Analyst point of view about industry news (product release, M&A, start-up, fund-raising, etc.) from a patent perspective.

Format • Knowmade website

MAIN FIELDS OF EXPERTISE

SEMICONDUCTORS

- Materials & Substrates
- Power electronics
- RF & Wireless datacom
- MEMS, Sensing & Imaging
- Photonics, Lighting & Display
- > Memory
- Packaging

ENERGY

- Batteries
- ➤ Fuel-cells
- Solar PV
- Power management



HEALTHCARE

- > New therapeutic tools
- Medical diagnostics
- Medical devices and imaging
- Drug discovery and delivery

AGRI-FOOD

- Food processing & formulation
- Vegan food
- Next-gen packaging
- Microbiology





SANJOIN

www.knowmade.com contact@knowmade.fr KnowMade S.A.R.L., 2405 route des Dolines, 06902 Sophia Antipolis, France